Acyltransferases

(S)-(+)-Etomoxir is the S enantiomer of Etomoxir, an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a). This compound effectively inhibits fatty acid oxidation (FAO) by targeting CPT-1a, thereby reducing palmitate β-oxidation in human, rat, and guinea pig tissues. (S)-(+)-Etomoxir is widely used in research related to metabolism, obesity, and diabetes to explore the role of fatty acid metabolism in various physiological and pathological conditions.

(R)-2-(3-(2-Ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxylic Acid serves as an important synthetic intermediate in the development of Ervogastat, a diacylglycerol acyltransferase 2 (DGAT-2) inhibitor. Its role in the synthesis of DGAT-2 inhibitors highlights its significance in studying lipid metabolism and potential therapeutic applications in managing metabolic disorders. Researchers can utilize this compound to further investigate the modulation of lipid synthesis pathways.

BMS-986172 is a selective inhibitor of Monoacylglycerol acyltransferase 2 (MGAT2), demonstrating an IC50 of 4.6 nM for human MGAT2 and 20 nM for mouse MGAT2. This orally active compound has been shown to reduce food intake and body weight, making it a valuable tool for researching metabolic disorders, particularly obesity. Its efficacy in modulating MGAT2 activity supports its potential in addressing various metabolic diseases.

(Rac)-OSMI-1 is a racemic mixture of OSMI-1, a potent inhibitor of O-GlcNAc transferase (OGT) that exhibits an IC50 value of 2.7 μM. This compound effectively inhibits O-linked N-acetylglucosamine (O-GlcNAcylation) in various mammalian cell lines, while not significantly affecting cell surface N- or O-linked glycans. Its application spans diverse studies in cellular signaling and glycosylation modifications, making it a valuable tool for research into OGT-related biological processes.

ANAT inhibitor-2 is a selective inhibitor of the enzyme arylacetamide deacetylase (ANAT), which plays a role in the metabolism of various substrates. With an IC50 value of 20 μM, this compound demonstrates significant inhibitory activity, making it an important tool for studying canavan disease and its underlying biochemical pathways. Research applications include investigations into metabolic disorders and the development of therapeutic strategies for genetic conditions associated with ANAT dysfunction.

AANAT-IN-1 is a potent inhibitor of aralkylamine N-acetyltransferase (AANAT), demonstrating an IC50 value of 10μM. AANAT plays a critical role in the synthesis of melatonin, a hormone implicated in various disorders, including seasonal affective disorder (SAD), characterized by dysregulated melatonin levels. This compound serves as a valuable research tool for studying the mechanisms of melatonin synthesis and its impact on seasonal mood fluctuations.

H2-003 is a selective inhibitor of human diacylglycerol O-acyltransferase 2 (DGAT2), targeting triglyceride biosynthesis. This compound demonstrates effectiveness in inhibiting lipid droplet formation in 3T3-L1 adipocytes, making it a valuable tool for studying DGAT2 function. H2-003 is applicable in research focusing on DGAT2 and metabolic disorders associated with triglyceride accumulation.

GERI-BP002-A is an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor derived from Aspergillus fumigatus F93. This compound is primarily utilized in cancer research, where it plays a crucial role in studying lipid metabolism and its impact on tumor progression. By inhibiting ACAT, GERI-BP002-A contributes to the alteration of cholesterol esters, facilitating investigations into lipid-related pathways in various cancer models.

Terpendole C is a potent acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor derived from Albophoma yamanashiensis. This compound exhibits significant biological activity in modulating lipid metabolism by inhibiting the conversion of cholesterol to cholesteryl esters. Terpendole C is widely utilized in research focusing on cholesterol-related disorders and lipid metabolism studies.

Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor that exhibits hypocholesterolemic activity. Isolated from the seeds of Zingiberaceae, it specifically inhibits rat hepatic ACAT with an IC50 value of 20.6 μM. This compound holds potential for research applications related to hypercholesterolemia and atherosclerosis, contributing to the understanding of cholesterol metabolism and cardiovascular health.

LDL-IN-1 is a potent antioxidant that effectively inhibits copper-mediated LDL oxidation, with an IC50 of 52 µM. Additionally, it serves as an inhibitor of Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2), exhibiting IC50 values of 60 µM. This compound is valuable for research into anti-atherosclerotic mechanisms and the modulation of cholesterol metabolism.

TMP-153 is a potent inhibitor of Acyl-CoA:cholesterol acyltransferase (ACAT) with an IC50 value ranging from 5-10 nM for hepatic and intestinal ACAT, demonstrated in preclinical studies. This compound effectively reduces cholesterol levels and is primarily utilized in research related to atherosclerosis and lipid metabolism. TMP-153's mechanism of action makes it a valuable tool for studying cholesterol-related disorders and their potential therapeutic interventions.

S-309309 is a selective inhibitor of MGAT2, an enzyme involved in glycan biosynthesis. This compound demonstrates oral bioactivity and has potential applications in metabolism-related research, particularly in the study of lipid metabolism and its implications in metabolic disorders. S-309309 may serve as a valuable tool for investigating the role of MGAT2 in cellular pathways and metabolic regulation.

2,6-Dichlorophenylacetic acid acts as an inhibitor of isopenicillin N synthase (IPNS) and acyl-CoA: 6-APA acyltransferase. This compound exhibits notable cytostatic activity against tumor cells, making it a valuable tool in cancer research. Its role in modulating bacterial cell wall biosynthesis positions it as a relevant agent for studying antibiotic mechanisms and drug development.

C12-Sphingosine is a short-chain sphingosine homologue that primarily targets serine palmitoyltransferase. This reagent is known to inhibit the activity of this enzyme in primary cultured cerebellar cells, making it valuable for studying sphingolipid metabolism and its implications in neurobiology. Its applications extend to exploring cellular signaling pathways and understanding the role of sphingolipids in various physiological and pathological processes.

OSMI-3 is a selective inhibitor of O-linked N-acetylglucosamine transferase (OGT), characterized by its potent and cell-permeable properties. This compound effectively modulates OGT activity, leading to the enhancement of retained intron splicing in cellular contexts. OSMI-3 is valuable in research investigating the role of OGT in cellular processes and its implications in various disease states.

ANAT inhibitor-1 is a selective inhibitor of human aspartate N-acetyltransferase (ANAT), specifically developed for research into canavan disease. By inhibiting ANAT, this compound plays a crucial role in studying the biochemical pathways disrupted in this disorder. Its application extends to elucidating the mechanisms underlying neurodegenerative conditions and developing potential therapeutic strategies.

ST1060 is a selective ceramide synthase 2 (CerS2) inhibitor. It effectively reduces the levels of long-chain dihydroceramide (dhCer) with IC50 values of 63.6 μM and 61.3 μM for C24:0 and C24:1, respectively. This compound is valuable for research applications involving lipid metabolism, cellular stress responses, and potential therapeutic strategies targeting sphingolipid pathways.

Eldacimibe is an inhibitor of acyl-CoA:cholesterol acyltransferase 2 (ACAT2), which plays a crucial role in cholesterol metabolism. This compound effectively reduces plasma cholesterol levels by inhibiting cholesterol absorption and preventing the transformation of macrophages into foam cells. Eldacimibe is applicable in research focused on cardiovascular diseases such as atherosclerosis, as well as endocrine and metabolic disorders, particularly hypercholesterolemia.